<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649945</url>
  </required_header>
  <id_info>
    <org_study_id>HRGX06</org_study_id>
    <nct_id>NCT03649945</nct_id>
  </id_info>
  <brief_title>Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer</brief_title>
  <official_title>An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized trial, it compares the efficacy and safety between apatinib
      combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year disease-free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>the percentage of the patients whose disease cannot be detected after curative therapy in three years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>From the time of randomization to the time of death for any reason.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel plus Nedaplatin combined with Endostar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel plus Nedaplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No medicine intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles</description>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_label>Test Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles</description>
    <arm_group_label>Test Group 1</arm_group_label>
    <arm_group_label>Test Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar</intervention_name>
    <description>7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles</description>
    <arm_group_label>Test Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IIA-IIIC phase esophageal squamous cell carcinoma confirmed by histopathology and
             immunohistochemistry.

          -  R0 resection has been performed at least before 4 weeks.

          -  ECOG PS score: 0-1 points.

          -  Estimated survival time: at least 12 weeks.

          -  No radiotherapy, chemotherapy or molecular targeted therapy before.

          -  Main organs are functional, which meet the following criteria:

        Blood Routine:

        HB≥90 g/L（No blood transfusion within 14 days）, ANC≥1.5×109/L, PLT ≥80×109/L. Biochemical
        examination： ALB≥30g / L（No blood transfusion within 14 days）, ALT&lt;2ULN； AST&lt;2ULN
        TBIL≤1.5ULN； Plasma Cr≤1.5ULN；

          -  Volunteer with signed informed consent form, good compliance and good follow-up
             cooperation.

          -  Patients who the investigator believws they can benefit.

        Exclusion Criteria:

          -  Those who have had other malignant tumors in the past or at the same time.

          -  Pregnant or lactating women.

          -  Patients with grade-II or higher myocardial ischemia or myocardial infarction, poorly
             controlled arrhythmias (including QTC interval ≥ 450 ms) and cardiac dysfunction
             according to NYHA criteria III to IV. Cardiac color Doppler examination: LVEF (left
             ventricular ejection) Score) &lt;50%.

          -  Have clear gastrointestinal bleeding concerns (such as local active ulcer lesions,
             fecal occult blood ++), and a history of gastrointestinal bleeding within 6 months.

          -  Have a history of mental illness or psychotropic substance abuse.

          -  Patients who have participated in other drug clinical trials within 4 weeks.

          -  According to the investigator's judgment, patients who are at a risk or have
             accompanying disease.

          -  Patients who believe that they are unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>August 26, 2018</last_update_submitted>
  <last_update_submitted_qc>August 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jie Ma</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Endostar protein</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

